Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metoprolol succinate + nebivolol refers to a comparative treatment regimen evaluated by the East Coast Institute for Research for the management of hypertension, specifically focusing on its impact on female sexual function. Metoprolol succinate is a cardioselective beta-1 adrenergic receptor antagonist that reduces heart rate and cardiac output. Nebivolol is a third-generation, highly selective beta-1 blocker that uniquely stimulates the endothelial nitric oxide synthase (eNOS) pathway, leading to vasodilation and reduced peripheral resistance. The evaluation of these two agents in a clinical trial context was designed to assess whether nebivolol's vasodilatory properties offer a superior side-effect profile regarding sexual dysfunction compared to traditional beta-blockers like metoprolol succinate in post-menopausal women.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metoprolol succinate + nebivolol (East Coast Institute for Research).